Treatment of Nonagenarians With Atrial Fibrillation: Insights From the Berlin Atrial Fibrillation (BAF) Registry.

[1]  O. Hanon,et al.  Comorbidities against Quality Control of VKA Therapy in Non-Valvular Atrial Fibrillation: A French National Cross-Sectional Study , 2015, PloS one.

[2]  N. Magné,et al.  General management of nonagenarian patients: a review of the literature. , 2014, Swiss medical weekly.

[3]  Jonathan H Seltzer,et al.  Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. , 2014, JAMA internal medicine.

[4]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[5]  D. Atar,et al.  Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial , 2014, European heart journal.

[6]  W. Aronow,et al.  Pharmacology of antiarrhythmic drugs in elderly patients. , 2012, Clinics in geriatric medicine.

[7]  G. Mead,et al.  Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. , 2011, Age and ageing.

[8]  V. Deneer,et al.  Is Antiarrhythmic Treatment in the Elderly Different? , 2011, Drugs & aging.

[9]  Ottavio Alfieri,et al.  Corrigendum to: ‘Guidelines for the management of atrial fibrillation’ [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420] , 2011 .

[10]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[11]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  G. Lip,et al.  Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. , 2010, Journal of the American College of Cardiology.

[13]  D. Singer,et al.  Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.

[14]  G. Lamas,et al.  Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective , 2008, Journal of medical economics.

[15]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[16]  K. Stangl,et al.  Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. , 2000, Journal of the American College of Cardiology.

[17]  Bramahn . Singh,et al.  Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. , 1999, Journal of the American College of Cardiology.

[18]  Hao Wang,et al.  Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. , 2015, Chest.